慢性阻塞性肺疾病急性加重期血清MMP-9、TIMP-1变化的临床意义

目的探讨慢性阻塞性肺疾病（COPD）急性加重期血清基质金属蛋白酶-9（MMP-9）、基质金属蛋白酶组织抑制剂-1（TIMP-1）变化的临床意义。方法选取COPD急性加重期患者55例（COPD组）、查体健康者20例（对照组）,根据COPD组肺功能及病情程度分为轻度组15例、中度组22例、重度组18例。采用酶联免疫吸附法检测各组血清MMP-9及TIMP-1;行肺功能通气检查,记录第1秒钟用力呼吸容积（FEV1）/用力肺活量（FVC）及FEV1占预计值的百分比（FEV1%）。分析COPD组血清MMP-9、TIMP-1水平与病情严重程度的相关性。结果 COPD组血清MMP-9、TIMP-1明显高于对照组,且随病情加重逐渐升高（P〈0.01或〈0.05）;直线相关分析显示,COPD组血清MMP-9、TIMP-1水平与FEV1%呈负相关（r分别为-0.783、-0.776,P均〈0.01）。结论血清MMP-9、TIMP-1水平与COPD病情程度相关,病情越重,MMP-9、TIMP-1越高,且与FEV1%呈负相关;提示血清MMP-9、TIMP-1变化可作为判定COPD病情严重程度的指标之一。     

慢性阻塞性肺疾病患者血清MMP-9检测及意义

目的探讨基质金属蛋白酶-9（MMP-9）在慢性阻塞性肺疾病（COPD）气道炎症发生、发展过程中的作用。方法采用ELISA法测定56例COPD患者（观察组）急性加重期（56例）及稳定期（52例）血清MMP-9水平,并与50例同期健康体检者（对照组）比较,对MMP-9表达与第一秒用力呼气容积占预计值的百分比（FEV1%）、一秒钟用力呼气容积占用力肺活量的百分比（FEV1/FVC）%、残气量与肺总量之比（RV/TLC）%行相关性分析。结果 COPD急性加重期及稳定期患者血清MMP-9水平均明显高于对照组（P〈0.01,P〈0.05）,且与FEV1%呈负相关（r=-0.712,P〈0.05）,与（RV/TLC）%呈正相关（r=0.691,P〈0.05）。结论 MMP-9参与了COPD气道炎症的发生、发展;检测血清MMP-9水平有助于判断COPD病情及预后。     

慢性阻塞性肺疾病患者组织基质金属蛋白酶-9、基质金属蛋白酶抑制剂-1及血管内皮生长因子测定的临床价值

目的:探讨慢性阻塞性肺疾病(COPD)急性加重期及稳定期患者,血清组织基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶抑制剂-1(TIMP-1)、血管内皮生长因子(VEGF)的浓度变化及相关性。方法:用酶联免疫吸附法(ELISA)测定73例COPD患者(急性加重期34例,稳定期39例)及对照组32例受试者血清MMP-9、TIMP-1、VEGF的浓度(ng/m L)。结果:(1)COPD患者血清VEGF、MMP-9及TIMP-1的水平以及MMP-9/TIMP-1比值均明显高于正常对照组,急性加重期COPD患者上述指标升高尤为显著。(2)COPD组中,MMP-9与TIMP-1正相关,VEGF与MMP-9、TIMP-1、MMP-9/TIMP-1比值分别具有正相关性。(3)COPD组患者血浆中MMP-9、TIMP-1浓度、MMP-9/TIMP-1浓度比值、VEGF浓度与FEV1/FVC%、FEV1占预计值%均呈负相关性。结论:COPD患者血清MMP-9浓度、TIMP-1浓度、MMP-9/MMP-1比率及VEGF浓度升高,并且与气流阻塞程度成负相关,可以作为评价患者病情严重程度的指标。     

基质金属蛋白酶9、基质金属蛋白酶抑制剂1和转化生长因子β1的表达与支气管哮喘不可逆性气流阻塞

目的探讨基质金属蛋白酶9（MMP-9）及基质金属蛋白酶抑制剂1（TIMP-1）和转化生长因子β1（TGF-β1）在支气管哮喘（简称哮喘）不可逆气流阻塞中的表达。方法2008年6月至12月就诊于山西医科大学第一医院的哮喘患者48例,根据应用β2受体激动剂后是否出现气流可逆,将哮喘患者分为可逆气流阻塞组（24例）不可逆气流阻塞组（24例）以及对照组（10名）。通过盐水诱导痰液,利用ELISA方法检测哮喘患者及对照者血清、诱导痰中的MMP-9、TIMP-1和TGF-β1浓度。结果哮喘患者血清及痰液中的MMP-9、TIMP-1和TGF-β1含量均高于对照组,不可逆气流阻塞组含量高于可逆气流阻塞组。血清与痰液中的该三种因子有良好的相关性。哮喘组血清及痰液中的MMP-9／TIMP-1比值均低于对照组,不可逆气流阻塞组痰液中的MMP-9／TIMP-1比值比可逆气流阻塞组减小,血中无变化。结论采用诱导痰的方法来获取气道内的分泌物是一种安全有效的方法。痰液和血清中的MMP-9、TIMP-1和TGF-β1均可以作为哮喘不可逆气流阻塞的生物标记物,痰液中的MMP-9／TIMP-1的比值比血清中更敏感地预测哮喘的不可逆气流阻塞。     

开角型青光眼患者房水中MMP-3、TIMP-1的表达及意义

目的检测开角型青光眼患者房水中基质金属蛋白酶（MMP）-3及金属蛋白酶组织抑制因子（TIMP）-1的表达,并探讨其意义。方法采用酶联免疫反应（ELISA）双抗体夹心法检测开角型青光眼（A组）和年龄相关性白内障（B组）患者房水中MMP-3和TIMP-1的水平。结果A、B两组MMP-3水平分别为（68.0310±4.1400）、（69.7941±2.1315）μmol/L;TIMP-1水平分别为（6.7604±0.6632）、（3.1617±0.1603）μmol/L,MMP-3/TIMP-1分别为9.9017±0.3447、22.0592±1.0172,以上指标两组相比,P均〈0.05。结论开角型青光眼患者房水中MMP-3表达,TIMP-1表达升高,二者共同促进细胞外基质的异常堆积从而参与了开角型青光眼的发病机制。     

孟鲁司特钠对支气管哮喘患者血清MMP-9和TIMP-1水平的影响

目的 通过采用酶联免疫吸附试验（ELISA）法测定支气管哮喘（简称哮喘）治疗前后血清中基质金属蛋白酶-9（matrix metalloproteinase-9,MMP-9）和基质金属蛋白酶组织抑制剂1（tissue inhibitor of metalloproteinases-1,TIMP-1）水平,观察白三烯受体拮抗剂孟鲁司特钠对轻度持续性哮喘患者血清中MMP-9和TIMP-1水平的影响.方法 选取轻度持续性哮喘患者61例,随机分成治疗组29例和对照组32例,治疗组使用常规治疗＋孟鲁司特钠10 mg每日一次口服,疗程为7～14 d,对照组使用常规治疗,疗程为7～14 d,采用ELISA法测定两组治疗前后血清MMP-9和TIMP-1水平,并对其变化进行分析比较.结果 ①治疗后治疗组血清MMP-9水平[（22.75±6.51） μg/L]明显低于对照组治疗后[（28.93±7.59）μg/L]（P＜0.05）;治疗组治疗前血清MMP-9水平[（29.07±7.83） μg/L]明显高于治疗组治疗后[（22.75±6.51）μg/L]（P＜0.05）.②治疗后治疗组血清TIMP-1[（10.74±4.14） μg/L]明显低于对照组治疗后[（13.75±2.59） μg/L]（P＜0.05）;治疗组治疗前血清TIMP-1水平[（13.76±3.53） μg/L]明显高于治疗组治疗后[（10.74±4.14） μg/L]（P＜0.05）.结论 孟鲁司特钠可明显降低轻度持续性哮喘患者血清中MMP-9和TIMP-1的水平.MMP-9和TIMP-1的水平可作为轻度持续性哮喘患者疗效判断的指标之一.孟鲁司特钠可能会通过下调哮喘患者血清MMP-9和TIMP-1的水平,减少气道细胞外基质沉积.     

慢性阻塞性肺疾病患者血清基质金属蛋白酶及其抑制因子与细胞黏附因子和血管内皮黏附因子的关系研究

目的探讨慢性阻塞性肺疾病(COPD)患者血清基质金属蛋白酶-9(MMP-9)及其抑制因子(TIMP-1)的变化与细胞黏附因子-1(ICAM-1)、血管内皮黏附因子-1(VCAM-1)之间的关系。方法应用酶联免疫吸附试验(ELISA)检测2005年1月至7月哈尔滨医科大学附属第一医院呼吸内科收治的58例COPD患者和同期来医院进行健康体检的30名正常人血清中MMP-9,TIMP-1、ICAM-1和VCAM-1的质量浓度,将MMP-9、TIMP-1和MMP-9/TIMP-1比值与ICAM-1、VCAM-1及第一秒用力呼气容积(FEV1)占预计值百分比(FEV1%)、1秒率(FEV1/FVC%)进行相关性分析。结果(1)COPD患者的MMP-9、TIMP-1、ICAM-1、VCAM-1血清质量浓度[(128.89±115.84),(228.28±107.13),(203.98±70.37),(352.98±117.73)μg/L]明显高于对照组[(30.65±18.43),(133.69±41.41),(148.35±23.77),(233.57±36.65)μg/L],差异均具有显著性意义(P均<0.01)。(2)COPD组血清MMP-9与ICAM-1、VCAM-1质量浓度呈正相关(P均<0.05);血清TIMP-1与ICAM-1、VCAM-1质量浓度呈正相关(P均<0.01);血清MMP-9、TIMP-1、ICAM-1、VCAM-1质量浓度与FEV1%及FEV1/FVC%均呈明显负相关(P均<0.01);MMP-9/TIMP-1比值与FEV1%及FEV1/FVC%均具有明显负相关(P均<0.05)。结论(1)COPD患者血中ICAM-1、VCAM-1增加与MMP-9、TIMP-1增加具有相关性,是COPD发病中基质金属蛋白酶降解细胞外基质的重要调节因素。(2)COPD患者血清MMP-9、TIMP-1明显增加,MMP-9/TIMP-1比值增加,与气流阻塞成负相关,MMP-9、TIMP-1是引起气流阻塞很重要的因素。     

支气管哮喘和慢性阻塞性肺疾病患者诱导痰中基质金属蛋白酶及其抑制剂与气道炎症及气流受限

目的探讨支气管哮喘（简称哮喘）和慢性阻塞性肺疾病（COPD）患者诱导痰中基质金属蛋白酶9（MMP-9）和基质金属蛋白酶抑制剂1（TIMP-1）的水平及其与炎性细胞数、肺功能的关系。方法分别选择14例缓解期哮喘患者（哮喘组）、12例稳定期COPD患者（COPD组）和10名健康对照者（健康对照组）进行肺功能测定和用诱导痰检查方法对痰炎性细胞进行分类计数，并用酶联免疫吸附试验（ELISA）法测定诱导痰上清液中自细胞介素4（IL-4）、MMP-9和TIMP-1浓度。结果哮喘组患者诱导痰中嗜酸粒细胞、中性粒细胞分别为0．181±0．067、0．30±0．07，健康对照组为0．007±0．005、0．26±0．06，COPD组为0．042±0．017、0．50±0．10，3组细胞间比较差异有统计学意义（F值分别为4．32、4．13，P均〈0．05）。哮喘组、COPD组、健康对照组间诱导痰中IL-4浓度分别为（19±7）×10^-3／L、（14±6）×10^-3g／L、（11±4）×10^-3g／L，3组诱导痰中IL-4浓度比较差异无统计学意义（F=1．56，P均〉0．05），且分别与嗜酸粒细胞、中性粒细胞和第一秒用力呼气容积占预计值百分比（FEV1占预计值％）无相关（r分别为0．33、0．11、0．19、0．25、0．39、0．40、0．21、0．35、0．17，P均〉0．05）。哮喘组和COPD组诱导痰中MMP-9、TIMP-1浓度分别为（15．9±6．0）g／L、（13．4±5．1）g／L、（19．8±8．5）g／L、（16．7±7．6）g／L，健康对照组分别为（1．8±1．1）g／L、（1．3±0．9）g／L，两组MMP-9、TIMP-1浓度比较差异有统计学意义（F值分别为2．99、4．22，P均〈0．05）。哮喘组MMP-9浓度与嗜酸粒细胞呈正相关（r=0．71，P〈0．05）；COPD组MMP-9浓度与中性粒细胞呈正相关（r=0．59，P〈0．05），但与FEV。占预计值％和第一秒用力呼气容秽用力肺活量（FEV1／FVC）无相关（r分别为0．22、0．16、0．25、0．30，P均〉0．05）。哮喘组和COPD组TIMP．1浓度均与嗜酸粒细胞和中性粒细胞无相关（r分别为0．27、0．31、0．20、0．35，P均〉0．05），但与FEV。占预计值％呈负相关（r分别为-0．58、-0．62，P均〈0．05）。哮喘组和COPD组诱导痰中MMP-9／TIMP-1比值分别为0．8±0．7、0．8±0．6，两组比较差异无统计学意义（F=1．78，P〉0．05），但与健康对照组（1．5±0．6）比较差异有统计学意义（F=3．70，P〈0．05），且与FEV1占预计值％呈正相关（r分别为0．56、0．61，P均〈0．05）。结论哮喘组和COPD组患者诱导痰中MMP-9／TIMP-1比值的失衡与气道炎症和气流受限有关，这种失衡在哮喘和COPD细胞外基质的重塑和气流受限的发病机制中发挥重要作用。     

支气管扩张症合并不可逆气流阻塞患者的临床特征

目的 探讨支气管扩张症（简称支扩症）合并不可逆气流阻塞患者的临床特征。方法纳入2017年1月~6月于我科就诊的稳定期支扩症患者60例,根据应用β₂受体激动剂后肺功能中第1秒用力呼气容积（FEV₁）/用力肺活量（FVC）,将其分为可逆气流阻塞组(FEV₁/FVC≥70%)26例和不可逆气流阻塞组(FEV₁/FVC<70%)34例,选取于我院体检中心体检的健康者10例作为对照组。比较3组受试者的痰液基质金属蛋白酶-9（MMP-9）、基质金属蛋白酶抑制剂-1（TIMP-1）水平、MMP-9/TIMP-1、肺功能及支扩症严重程度评分（FACED评分）。不可逆气流阻塞组患者按照随机数字表分为常规治疗组（A组）和吸入噻托溴铵组（B组）,每组各17例。比较A组和B组患者痰液MMP-9、TIMP-1水平、MMP-9/TIMP-1、肺功能及FACED评分。结果 可逆气流阻塞组、不可逆气流阻塞组及对照组受试者吸烟时间、FACED评分、MMP-9/TIMP-1、FEV-1占预计值的百分比(FEV₁%pred)、FVC占预计值的百分比(FVC%pred)及FEV₁/FVC比较,差异均有统计学意义（P<0.05）。其中不可逆气流阻塞组患者吸烟时间和FACED评分均高于可逆气流阻塞组（P<0.05）;不可逆气流阻塞组患者FACED评分、痰液MMP-9、MMP-9/TIMP-1均高于可逆气流阻塞组和对照组,FEV₁%pred、FVC%pred、FEV₁/FVC均低于可逆气流阻塞组和对照组（P<0.05）。治疗前A组和B组患者FACED评分、痰液MMP-9、TIMP-1、MMP-9/TIMP-1及肺功能指标比较,差异均无统计学意义（P>0.05）。B组患者治疗后FACED评分、痰液MMP-9、TIMP-1均低于同组治疗前,FEV₁%pred和FVC%pred均高于同组治疗前（P<0.05）;A组患者治疗后仅TIMP-1低于同组治疗前（P<0.05）,而治疗前后FACED评分、痰液MMP-9、TIMP-1、MMP-9/TIMP-1及肺功能指标比较,差异均无统计学意义（P>0.05）。治疗后B组患者FEV₁%pred和FVC%pred均高于A组（P＜0.05）。结论 合并不可逆气流阻塞的支扩症患者气道重塑更明显,肺通气功能更差,病情更严重,长期规律吸入噻托溴铵对存在不可逆气流阻塞的支扩症患者有效。     

丹参对慢性阻塞性肺疾病患者血清MMP-9、TIMP-1的影响

目的探讨丹参对慢性阻塞性肺疾病(COPD)急性加重期患者血清MMP-9、TIMP-1的影响。方法选择COPD急性加重期的中重度患者60例分为A组(丹参组)30例、B组(常规组)30例,另设C组(健康对照组)30例。A组在常规治疗基础上加入丹参注射液800mg,每日1次静滴,疗程7～10d。A、B组患者急性期及治疗后稳定期与C组均应用酶联免疫吸附法分别检测血清MMP-9、TIMP-1水平、MMP-9/TIMP-1比值。结果 A、B组血清MMP-9水平、TIMP-1水平、MMP-9/TIMP-1比值急性期明显高于稳定期(P0.05),稳定期亦高于C组(P0.05);A组和B组比较,急性期血清MMP-9水平无统计学差异(P0.05),缓解期MMP-9水平A组低于B组(P0.05);急性期、缓解期血清TIMP-1水平、MMP-9/TIMP-1比值均无统计学差异(P0.05)。结论 MMP-9参与了COPD的气道炎症过程,TIMP-1参与了COPD的气道修复过程,在COPD的发病中存在MMP-9/TIMP-1失衡,丹参可能对基质金属蛋白酶有抑制作用,从而对COPD患者有一定保护和治疗作用。     

Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients.

Matrix metalloproteinase (MMP)-9 and tissue inhibitors of metalloproteinase (TIMP)-1 concentrations are increased in the sputum of asthma and chronic bronchitis patients, and are thought to be related to airflow obstruction. However, serum concentrations of these enzymes have not been clearly evaluated in patients with chronic obstructive pulmonary disease (COPD). The aim of this study was to examine the serum concentrations of these enzymes in COPD and asthmatic patients in order to determine their relationship with airway obstruction. Serum samples were obtained from 72 patients with COPD: 66 control subjects and 26 patients with asthma. Smoking histories of control subjects were matched with those of COPD patients. Serum concentrations of TIMP-1 and MMP-9 were determined by ELISA. The circulating TIMP-1 concentration was significantly higher in stable COPD patients than in control and asthmatic subjects, and was significantly negatively correlated with forced expiratory volume in one second/forced vital capacity in COPD patients. The molar ratio between MMP-9 and TIMP-1 was significantly lower in COPD patients than in control subjects. In patients with COPD, the serum TIMP-1 concentration was significantly increased during disease exacerbation. In conclusion, the current findings suggest that serum tissue inhibitors of metalloproteinase-1 concentration can be used as a serum marker of airway obstruction and exacerbation in chronic obstructive pulmonary disease patients.     

OSAHS、OSAHAHT最者血清基质金属蛋白酶9及其抑制因子水平

目的 探讨阻塞性睡眠呼吸暂停低通气综合征（obstructive sleep apnea-hypopnea syndrome，OSAHS）、阻塞性睡眠呼吸暂停低通气综合征相关性高血压（obstructive sleepapnea-hypopnea associated hypertension，OSAHAHT）患者血清基质金属蛋白酶9（MMP-9）及其抑制剂，基质金属蛋白酶组织抑制因子1（TIMP-1）水平的变化。方法 用酶联免疫吸附法对20例OSAHS、OSAHAHT患者血清MMP-9和TIMP-1水平测定，与16例健康对照组进行比较。结果 OSAHS、OSAHAHT患者血清MMP-9水平较正常对照组明显升高，有显著统计学意义，TIMP-1在OSAHS与对照组无明显差异，在OSAHAHT与对照组有明显差异，OSAHS、OSAHAHT患者血清MMP-9与反映睡眠呼吸暂停严重程度的指标有明显相关性。结论 OSAHS、OSAHAHT患者存在MMP-9及TIMP-1代谢的异常，血清MMP-9可反映睡眠呼吸暂停病情的严重程度。     

Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease,idiopathic pulmonary fibrosis and healthy subjects

BACKGROUND: Matrix-metalloproteinases (MMPs) and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), are involved in the turnover of extracellular matrix. Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are inflammatory diseases characterized by excessive matrix degradation and tissue fibrosis. We have compared sputum concentrations of MMP-9, TIMP-1 and the controlling cytokine tumor necrosis factor (TNF)-alpha in patients with COPD, IPF and healthy subjects. METHODS: In a cross-sectional analysis, 12 patients with stable COPD, 15 patients with IPF and 14 healthy subjects underwent sputum induction. Induced sputum cells were counted and concentrations of MMP-9, TIMP-1 and TNF were measured by enzyme immunoassays. RESULTS: Sputum neutrophils were markedly elevated in COPD and IPF patients compared with controls (P<0.001, both comparisons). Concentrations of MMP-9 and the MMP-9:TIMP-1 ratio were increased in COPD (P<0.001 vs. IPF and controls), whereas sputum TIMP-1 levels were both elevated in COPD and IPF (P<0.01 vs. controls, both comparisons). TNF levels were similar in all three groups (P>0.2, all comparisons). MMP-9 concentrations were negatively correlated with airway obstruction (FEV1 FVC) in COPD (rho=-0.62, P=0.03), but not with diffusion capacity or vital capacity (% predicted) in IPF (rho=-0.06, P=0.85, and rho=-0.3, P=0.29, respectively). MMP-9 was positively correlated with sputum neutrophils in all patients (rho=0.68, P<0.0001), and with TNF in COPD patients (rho=0.76, P=0.004). CONCLUSIONS: These data underline the significance of protease/antiprotease imbalance for the pathogenesis of inflammatory lung diseases. Despite similar cellular inflammatory patterns both in COPD and IPF sputa, marked differences were observed with regard to MMP-9:TIMP-1 balance.     

Enhanced Exhalation of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Patients with COPD Exacerbation: A Prospective Study

Background: Matrix metalloproteinase-9 (MMP-9) and its inhibitor tissue inhibitor of metalloproteinase-1 (TIMP-1) are involved in the pathogenesis of airway inflammation in patients with chronic obstructive pulmonary disease (COPD). However, no study so far has addressed their value as noninvasive biomarkers of airways inflammation. Objective: To evaluate MMP-9 and TIMP-1 concentrations in the exhaled breath condensate (EBC) of patients with stable COPD and also during the exacerbation episode. Methods: EBC and serum samples were collected in 17 stable-phase COPD patients who were current smokers as well as during their first exacerbation episode, and in 22 asymptomatic smokers. EBC and serum levels of MMP-9 and TIMP-1 were measured with ELISA kit. Results: Mean EBC MMP-9 and TIMP-1 levels were higher in patients with stable COPD than in asymptomatic smokers. Exacerbation of COPD increased 2-fold the exhalation of MMP-9 (18.5 ± 10.1 ng/ml vs. 8.9 ± 6.2 ng/ml, p = 0.01) and TIMP-1 (to 41.1 ± 20.4 ng/ml vs. 16.4 ± 6.8 ng/ml, p < 0.001). Both, MMP-9 and TIMP-1 in EBC correlated negatively with FEV(1) (% predicted) at baseline (r = -0.78, p < 0.001 and r = -0.73, p < 0.001) and during the exacerbation episode (r = -0.57, p = 0.02 and r = -0.65, p = 0.005). Similar negative correlations were noted with FVC (% predicted), except for MMP-9 in EBC at exacerbation. Exhaled MMP-9 and TIMP-1 did not correlate with serum concentrations in COPD patients, either at baseline or during exacerbation. Conclusion: Exhaled MMP-9 and TIMP-1 increased during COPD exacerbation and was negatively correlated with spirometric variables, which suggests the usefulness of their measurement in EBC for the monitoring of airways inflammation. However, to better assess their diagnostic or prognostic value larger studies are necessary.     

慢性阻塞性肺疾病急性加重期患者痰MMP-9和TIMP-1的变化

目的检测慢性阻塞性肺疾病（COPD）患者痰基质金属蛋白酶-9（MMPO）和基质金属蛋白酶抑制剂-1（TIMP-1）的变化,探讨COPD患者肺功能下降与MMPO、TIMP-1的关系。方法COPD急性加重期患者20例、稳定期患者12例和9例健康对照者提供了痰标本,同时进行肺功能测定。采用双夹心抗体酶联免疫吸附测定实验检测痰上清液MMPO、TIMP-1含量。结果痰上清液MMPO浓度COPD急性加重期组高于稳定期组和对照组（P〈0．01）,稳定期组高于对照组（P〈0．05）;痰上清液MMPO／~MP．1浓度COPD急性加重期组高于稳定期组和对照组（P〈0．001）,稳定期组低于对照组（P〈0．05）。COPD急性加重期患者痰MMPO、MMPO／TIMP-1与第一秒用力呼气容积占预计值百分比（FEV,％pre）呈负相关（r=-0．573、P〈0．05,r=-0．625、P〈0．05）。结论COPD患者急性加重时痰MMP-9增加、MMPO／TIMP-1失衡,并且可能是肺功能下降的原因。     

Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer

AIM:To evaluate the levels of preoperative serum matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in gastric cancer.METHODS:One hundred gastric cancer patients who underwent gastrectomy were enrolled in this study.The serum concentrations of MMP-1 and TIMP-1 in these patients and in fifty healthy controls were determined using an enzyme-linked immunosorbent assay.RESULTS:Higher serum MMP-1 and TIMP-1 levels were observed in patients than in controls (P < 0.001).Serum M...     

基质金属蛋白酶-9及其抑制剂在重度慢性阻塞性肺疾病急性加重期的变化

目的探讨基质金属蛋白酶母（MMP-9）及其抑制剂-1（TIMP-1）在重度慢性阻塞性肺疾病急性加重期（AECOPD）的变化及其临床意义。方法应用酶联免疫吸附试验（ELISA）检测35例健康者（对照组）、40例COPD稳定期和急性加重期患者的血清MMP-9和T1MP-1水平,并分析其与肺功能的关系。结果稳定期COPD组MMP-9高于对照组,但两组MMP-9比较差异无统计学意义（P〉0．05）,TIMP-1、MMP-9／TIMP-1均高于对照组（P均〈0．05）;AECOPD组的血清MMP-9、TIMP-1、MMP-9／TIMP-1均高于对照组（分别为P〈0．01,P〈0．05,P〈0．05）;与稳定期比较,AECOPD组MMP-9、TIMP-1、MMP-9／TIMP-1升高（均P〈0．05）;AECOPD组血清MMP-9、TIMP-1、MMP-9／TIMP-1与FEV。％占正常预计值均呈负相关（P均〈0．05）,与稳定期组比较,AECOPD组FEV1、FEV1％占正常预计值有明显下降（P均〈0．05）。结论AECOPD患者血清MMP-9、TIMP-1和MMP-9／TIMP-1比值增加,均与FEV,％占正常预计值呈负相关;MMP-9／TIMP-1比例失衡,可能是导致重度AECOPD肺功能下降的机制之一。     

慢性阻塞性肺疾病血清基质金属蛋白酶-9和组织型金属蛋白酶抑制物-1的检测及其意义

目的 检测慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)急性加重期、稳定期患者和健康对照者血清中基质金属蛋白酶-9 (matrix metalloproteinase-9,MMP-9)和组织型金属蛋白酶抑制物-1 (tissue inhibitor of met...     

Systemic inflammation in COPD and asthma: similarities and differences]

While recent studies have shown that patients with COPD and patients with asthma exhibit evidence of airway and systemic inflammation, markers of systemic inflammation have not been compared between the two diseases. To evaluate circulating inflammatory markers, blood was sampled from 111 patients with COPD, 75 control subjects and 46 asthmatic patients (some of whom were smokers). Measurements of WCC, serum levels of fibrinogen, high-sensitivity c-reactive protein (hs-CRP), interleukin-8 (IL-8), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), transforming growth factor (TGF)-beta1, tissue inhibitors of metalloproteinase (TIMP)-1, neutrophil elastase and alphal-antitrypsin (alpha1-AT) were done. Serum TNF-alpha, IL-6, and TIMP-1 concentrations were significantly higher in patients with stable COPD and patients with asthma than in control patients. Serum alpha1-AT levels were significantly higher in COPD patients than in asthmatic patients and control subjects and serum TGF-beta1 levels were higher in asthma patients than in COPD patients. Smoking status had no effect on markers in COPD and asthmatic patients. Although COPD and asthma share common markers of systemic inflammation, serum levels of TGF-beta1 and alpha1-AT may reflect differences between the diseases.